Ventrus Biosciences, Inc.  (VTUS) Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease  
1/17/2012 10:01:27 AM

NEW YORK, Jan. 13, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), today announced the online publication of the prior Phase 2b study utilizing iferanserin (VEN 309), its novel investigational drug for the treatment of symptomatic hemorrhoids, in the peer reviewed journal Clinical Therapeutics. The article will appear in the February issue of Clinical Therapeutics and is currently available online at the following link Data from this trial have been previously disclosed by the company.